NBDF’s Commitment to Shared Decision-Making and Evidence-Based Access in Gene Therapy

The current coverage environment can create challenges for individuals seeking to explore gene therapy as a potential treatment option, as well as for clinicians and hemophilia treatment centers managing both clinical care and administrative demands. We believe treatment decisions should be individualized, clinically appropriate, and informed by both the available evidence and patient preferences.

Source: National Bleeding Disorders Foundation, NBDF Notes, February 2026